Publications by authors named "E Nicolas-Virelizier"
Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management.
View Article and Find Full Text PDFArticle Synopsis
- * Out of 89 participants, the treatment achieved a complete metabolic response (CMR) in 77.5% of cases after 6 cycles, with a tolerance for side effects, as 88% completed the regimen despite a 20% rate of serious adverse events.
- * In long-term follow-up (median 42 months), the 4-year progression-free survival rate was 50% and overall survival 69%, with factors like liver involvement and lymphopenia affecting outcomes.
Background: t-AML occurs after a primary malignancy treatment and retains a poor prognosis.
Aims: To determine the impact of primary malignancies, therapeutic strategies, and prognostic factors on clinical outcomes of t-AML.
Results: A total of 112 adult patients were included in this study.